2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older: United States, 2015*

(2015) David K. Kim et al.   ANNALS OF INTERNAL MEDICINE

FRI0261 Tnf Inhibitor Therapy and Risk of Breast Cancer Recurrence in Patients with Rheumatoid Arthritis– A Nationwide Cohort Study

(2014) P. Raaschou et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy

(2014) Huifeng Yun et al.   ANNALS OF THE RHEUMATIC DISEASES

Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study

(2014) P Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety of Etanercept and Methotrexate in Patients with Rheumatoid Arthritis and Hepatitis C Virus Infection: A Multicenter Randomized Clinical Trial

(2014) F. Iannone et al.   JOURNAL OF RHEUMATOLOGY

Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial

(2014) Hideto Kameda et al.   Modern Rheumatology

Which subgroup of rheumatoid arthritis patients benefits from switching to tocilizumab versus etanercept after previous infliximab failure? A retrospective study

(2014) Hiroki Wakabayashi et al.   Modern Rheumatology

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

(2014) Eun Bong Lee et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis

(2014) Paul Emery et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Higher Methotrexate Dose With Lymphoproliferative Disease Onset in Rheumatoid Arthritis Patients

(2014) Tomohiro Kameda et al.   ARTHRITIS CARE & RESEARCH

Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis

(2013) Marije F. Bakker   ANNALS OF INTERNAL MEDICINE

Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis

(2013) Joel Kremer et al.   ANNALS OF INTERNAL MEDICINE

Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)

(2013) Frank Buttgereit et al.   ANNALS OF THE RHEUMATIC DISEASES

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial

(2013) Michael Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor

(2013) Leslie R Harrold et al.   ANNALS OF THE RHEUMATIC DISEASES

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study

(2013) Désirée van der Heijde et al.   ARTHRITIS AND RHEUMATISM

GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation's direction and strength

(2013) Jeffrey C. Andrews et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations

(2013) Jeff Andrews et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Randomized Controlled Trial of Entecavir Prophylaxis for Rituximab-Associated Hepatitis B Virus Reactivation in Patients With Lymphoma and Resolved Hepatitis B

(2013) Yi-Hsiang Huang et al.   JOURNAL OF CLINICAL ONCOLOGY

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

(2013) Cem Gabay et al.   LANCET

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

(2013) Gerd R Burmester et al.   LANCET

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial

(2013) Josef S Smolen et al.   LANCET

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial

(2013) Josef S Smolen et al.   LANCET

Management of patients with hepatitis B who require immunosuppressive therapy

(2013) Jessica P. Hwang et al.   Nature Reviews Gastroenterology & Hepatology

Therapies for Active Rheumatoid Arthritis after Methotrexate Failure

(2013) James R. O'Dell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis

(2013) Kyung-Wook Jo et al.   RESPIRATORY MEDICINE

Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort

(2013) K Chatzidionysiou et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis

(2013) Stephen S. Johnston et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Tumor necrosis factor-α inhibitors and chronic hepatitis C: A comprehensive literature review

(2013) Maurizio Pompili   WORLD JOURNAL OF GASTROENTEROLOGY

Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden

(2013) P. Raaschou et al.   BMJ-British Medical Journal

Non-randomized studies as a source of complementary, sequential or replacement evidence for randomized controlled trials in systematic reviews on the effects of interventions

(2013) Holger J. Schünemann et al.   Research Synthesis Methods

Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial

(2012) P H de Jong et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study

(2012) Juan J Gomez-Reino et al.   ANNALS OF THE RHEUMATIC DISEASES

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study

(2012) Michael E. Weinblatt et al.   ARTHRITIS AND RHEUMATISM

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial

(2012) Larry W. Moreland et al.   ARTHRITIS AND RHEUMATISM

The Influence of Anti-TNF Therapy on the Course of Chronic Hepatitis C Virus Infection in Patients with Inflammatory Bowel Disease

(2012) Ming Valerie Lin et al.   DIGESTIVE DISEASES AND SCIENCES

Association Between Vaccination for Herpes Zoster and Risk of Herpes Zoster Infection Among Older Patients With Selected Immune-Mediated Diseases

(2012) Jie Zhang et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes

(2012) Gordon Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

(2012) Ronald F van Vollenhoven et al.   LANCET

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

(2012) Ronald F. van Vollenhoven et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice

(2012) Jaclyn Anderson et al.   ARTHRITIS CARE & RESEARCH

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

(2012) Jasvinder A. Singh et al.   ARTHRITIS CARE & RESEARCH

Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis. Results of a 12 month open-label randomized study.

(2012) Carlomaurizio Montecucco et al.   ARTHRITIS RESEARCH & THERAPY

Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate

(2011) E. Coulson et al.   ANNALS OF THE RHEUMATIC DISEASES

Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy

(2011) J.-L. Lan et al.   ANNALS OF THE RHEUMATIC DISEASES

Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors

(2011) Meliha Crnkic Kapetanovic et al.   ARTHRITIS AND RHEUMATISM

Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: A magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients

(2011) Mikkel Østergaard et al.   ARTHRITIS AND RHEUMATISM

American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials

(2011) David T. Felson et al.   ARTHRITIS AND RHEUMATISM

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

(2011) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

(2011) Roy Fleischmann et al.   ARTHRITIS AND RHEUMATISM

Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts

(2011) Akihiro Tamori et al.   JOURNAL OF GASTROENTEROLOGY

Tocilizumab Monotherapy Reduces Arterial Stiffness as Effectively as Etanercept or Adalimumab Monotherapy in Rheumatoid Arthritis: An Open-label Randomized Controlled Trial

(2011) KENSUKE KUME et al.   JOURNAL OF RHEUMATOLOGY

Hepatitis B Virus (HBV) Reactivation in Patients Receiving Tumor Necrosis Factor (TNF)-Targeted Therapy

(2011) Roberto Pérez-Alvarez et al.   MEDICINE

Tuberculosis infection in rheumatic patients with infliximab therapy: experience with 157 patients

(2011) Christiane Aguiar Nobre et al.   RHEUMATOLOGY INTERNATIONAL

Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate

(2011) Yoshiya Tanaka et al.   ARTHRITIS CARE & RESEARCH

The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study

(2011) Jie Zhang et al.   ARTHRITIS RESEARCH & THERAPY

Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports

(2010) A. M. Evens et al.   ANNALS OF ONCOLOGY

Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis

(2010) Monica Todoerti et al.   Annals of the New York Academy of Sciences

Golimumab, a new human anti-tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

(2010) Joel Kremer et al.   ARTHRITIS AND RHEUMATISM

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) Daniel Aletaha et al.   ARTHRITIS AND RHEUMATISM

Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-α antagonist therapy: safe re-initiation of TNF-α blockers after appropriate anti-tuberculous treatment

(2010) B. Denis et al.   CLINICAL MICROBIOLOGY AND INFECTION

Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: Observational study of 30 cases in everyday practice

(2010) Éric Toussirot et al.   JOINT BONE SPINE

GRADE guidelines: 2. Framing the question and deciding on important outcomes

(2010) Gordon H. Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register

(2010) W. G. Dixon et al.   ARTHRITIS CARE & RESEARCH

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

(2009) A Finckh et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: A long-term followup study of thirty-two patients

(2009) Benjamin Terrier et al.   ARTHRITIS AND RHEUMATISM

Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

(2009) Paul Emery et al.   ARTHRITIS AND RHEUMATISM

Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial

(2009) Clifton O. Bingham et al.   ARTHRITIS AND RHEUMATISM

Use of tumor necrosis factor-α (TNF-α) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients

(2009) Sophia Li et al.   CLINICAL RHEUMATOLOGY

Chronic hepatitis B: Update 2009

(2009) Anna S. F. Lok et al.   HEPATOLOGY

Safety of Etanercept in Patients at High Risk for Mycobacterial Tuberculosis Infections

(2009) R. AGGARWAL et al.   JOURNAL OF RHEUMATOLOGY

Golimumab, a human antibody to tumour necrosis factor   given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

(2008) E C Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

Triple therapy in early active rheumatoid arthritis: A randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies

(2008) S. A. Saunders et al.   ARTHRITIS AND RHEUMATISM

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis

(2008) Kenneth G. Saag et al.   ARTHRITIS AND RHEUMATISM

Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases

(2008) I. Cavazzana et al.   AUTOIMMUNITY REVIEWS

Going from evidence to recommendations

(2008) Gordon H Guyatt et al.   BMJ-British Medical Journal

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

(2008) Gordon H Guyatt et al.   BMJ-British Medical Journal

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

(2007) M Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES